Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 3, 2014, Pages 329-336

  Lotta, L A ^a   Valsecchi, C ^a   Pontiggia, S ^a   Mancini, I ^a   Cannavo A ^a   Artoni, A ^a   Mikovic, D ^b   Meloni, G ^c   Peyvandi, F ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Blood Transfusion Institute of Serbia   (Serbia)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

ADAMTS13 protein, human; ELISA; Immune complexes; Thrombotic thrombocytopenic purpura; Von Willebrand factor

Indexed keywords

HEMOGLOBIN; IMMUNOGLOBULIN G; LACTATE DEHYDROGENASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPRECIPITATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MIDDLE AGED; PLASMAPHERESIS; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; VALIDATION STUDY; WESTERN BLOTTING;

ADAMTS13 PROTEIN, HUMAN; ELISA; IMMUNE COMPLEXES; THROMBOTIC THROMBOCYTOPENIC PURPURA; VON WILLEBRAND FACTOR;

ADAM PROTEINS; ADULT; ANTIGEN-ANTIBODY COMPLEX; AUTOIMMUNE DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; PROGNOSIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REGISTRIES; REPRODUCIBILITY OF RESULTS; VON WILLEBRAND FACTOR;

EID: 84896745023     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12494     Document Type: Article

References (24)

1. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-35.
2. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
3. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
4. Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S, Bevan D, Mackie I, Machin S. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 2008; 142: 819-26.
5. Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, Poullin P, Malot S, Vanhille P, Azoulay E, Galicier L, Lemiale V, Mira JP, Ridel C, Rondeau E, Pourrat J, Girault S, Bordessoule D, Saheb S, Ramakers M et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS ONE 2010; 5: e10208.
6. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043-9.
7. Lotta LA, Mariani M, Consonni D, Mancini I, Palla R, Maino A, Vucelic D, Pizzuti M, Mannucci PM, Peyvandi F. Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. Br J Haematol 2010; 151: 488-94.
8. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-8.
9. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94.
10. Scheiflinger F, Knobl P, Trattner B, Plaimauer B, Mohr G, Dockal M, Dorner F, Rieger M. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003; 102: 3241-3.
11. Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C, Zimmermann K, Scharrer I, Peyvandi F, Galbusera M, Remuzzi G, Bohm M, Plaimauer B, Lammle B, Scheiflinger F. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; 106: 1262-7.
12. Lachmann PJ, Walport MJ. Deficiency of the effector mechanisms of the immune response and autoimmunity. Ciba Found Symp 1987; 129: 149-71.
13. Schifferli JA, Taylor RP. Physiological and pathological aspects of circulating immune complexes. Kidney Int 1989; 35: 993-1003.
14. Voice JK, Lachmann PJ. Neutrophil Fc gamma and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes. Eur J Immunol 1997; 27: 2514-23.
15. Shashidharamurthy R, Hennigar RA, Fuchs S, Palaniswami P, Sherman M, Selvaraj P. Extravasations and emigration of neutrophils to the inflammatory site depend on the interaction of immune-complex with Fcgamma receptors and can be effectively blocked by decoy Fcgamma receptors. Blood 2008; 111: 894-904.
16. Karsten CM, Kohl J. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. Immunobiology 2012; 217: 1067-79.
17. Ferrari S, Knobl P, Kolovratova V, Plaimauer B, Turecek PL, Varadi K, Rottensteiner H, Scheiflinger F. Inverse correlation of free and immune complex-sequestered anti-ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10: 156-8.
18. De Cristofaro R, Peyvandi F, Palla R, Lavoretano S, Lombardi R, Merati G, Romitelli F, Di Stasio E, Mannucci PM. Role of chloride ions in modulation of the interaction between von Willebrand factor and ADAMTS-13. J Biol Chem 2005; 280: 23295-302.
19. Feys HB, Liu F, Dong N, Pareyn I, Vauterin S, Vandeputte N, Noppe W, Ruan C, Deckmyn H, Vanhoorelbeke K. ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. J Thromb Haemost 2006; 4: 955-62.
20. Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, Valsecchi C, Canciani MT, Fabris F, Zver S, Reti M, Mikovic D, Karimi M, Giuffrida G, Laurenti L, Mannucci PM. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93: 232-9.
21. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
22. Bettoni G, Palla R, Valsecchi C, Consonni D, Lotta LA, Trisolini SM, Mancini I, Musallam KM, Rosendaal FR, Peyvandi F. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10: 1556-65.
23. Reti M, Farkas P, Csuka D, Razso K, Schlammadinger A, Udvardy ML, Madach K, Domjan G, Bereczki C, Reusz GS, Szabo AJ, Prohaszka Z. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10: 791-8.
24. Fuchs TA, Kremer Hovinga JA, Schatzberg D, Wagner DD, Lammle B. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood 2012; 120: 1157-64.